Following an siRNA screen which identified the spliceosome as a potential target for cSCC therapy, small molecule inhibitors of the spliceosome targeting the splicing factor SF3B1/SF3b155 have also been studied on our cell lines (IC1, IC1MET, IC8, IC12, IC18, MET1 and MET4). This evidence concerns the gene GZMM and skin squamous cell carcinoma.